CCDC90B

Across TCGA pan-cancer cohorts, CCDC90B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCDC90B data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CCDC90B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC90B expression acts as an unfavorable survival marker.

HNSC, OV, and SKCM are the cancer types where CCDC90B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.013	0.768	<.001	48	view →
OV	OS	Median	All	0.361	0.842	.004	18	view →
SKCM	DFS	Median	All	0.058	0.757	<.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CCDC90B–HNSC (OS)

Open the HNSC breakdown →